/KNSA

KNSA Stock - Kiniksa Pharmaceuticals, Ltd.

Q: What is the analyst price target for KNSA?

Analyst price target information is not currently available for KNSA.

Q: What is KNSA's market cap?

Market capitalization information is not currently available for KNSA.

Healthcare|Biotechnology|NASDAQ

$38.60-6.13%

$2.52 (-6.13%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+36.0%upside

Target: $52.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for KNSA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.04

52W High$44.42

52W Low$18.12

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$423.24M	$270.26M	$220.18M	$38.54M	N/A
Gross Profit	$362.33M	$213.74M	$197.28M	$29.44M	$-3,805,000
Gross Margin	85.6%	79.1%	89.6%	76.4%	N/A
Operating Income	$-45,616,000	$-25,196,000	$9.77M	$-156,636,000	$-157,363,000
Net Income	$-43,193,000	$14.08M	$183.36M	$-157,924,000	$-161,381,000
Net Margin	-10.2%	5.2%	83.3%	-409.7%	N/A
EPS	$-0.60	$0.20	$2.64	$-2.30	$-2.61

Company Overview

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Visit Website

Earnings History & Surprises

KNSA

Beat Rate

63%

Last 19 quarters

Avg Surprise

+7.4%

EPS vs Estimate

Beats / Misses

12/6

1 met exactly

Latest EPS

$0.23

Q4 2025

EPS Surprise History

Q1 24

+136.4%

$0.04vs$-0.11

Q2 24

-78.6%

$-0.25vs$-0.14

Q3 24

+33.3%

$-0.06vs$-0.09

Q4 24

-662.4%

$-0.18vs$-0.02

Q1 25

-100.0%

$-0.12vs$-0.06

Q2 25

+450.0%

$0.11vs$0.02

Q3 25

+27.8%

$0.23vs$0.18

Q4 25

-30.3%

$0.23vs$0.33

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 24, 2026	$0.37	—	—	—
Q4 2025	Oct 28, 2025	$0.33	$0.23	-30.3%	✗ MISS
Q3 2025	Jul 29, 2025	$0.18	$0.23	+27.8%	✓ BEAT
Q2 2025	Apr 29, 2025	$0.02	$0.11	+450.0%	✓ BEAT
Q1 2025	Feb 25, 2025	$-0.06	$-0.12	-100.0%	✗ MISS
Q4 2024	Oct 29, 2024	$-0.02	$-0.18	-662.4%	✗ MISS
Q3 2024	Jul 23, 2024	$-0.09	$-0.06	+33.3%	✓ BEAT
Q2 2024	Apr 23, 2024	$-0.14	$-0.25	-78.6%	✗ MISS
Q1 2024	Feb 28, 2024	$-0.11	$0.04	+136.4%	✓ BEAT
Q4 2023	Oct 31, 2023	$-0.18	$-0.20	-11.1%	✗ MISS
Q3 2023	Jul 25, 2023	$-0.16	$-0.02	+87.5%	✓ BEAT
Q2 2023	May 2, 2023	$-0.18	$-0.18	0.0%	= MET
Q1 2023	Feb 28, 2023	$-0.23	$0.06	+126.1%	✓ BEAT
Q4 2022	Nov 1, 2022	$0.38	$0.67	+76.3%	✓ BEAT
Q3 2022	Aug 3, 2022	$-0.43	$-0.29	+32.6%	✓ BEAT
Q2 2022	May 3, 2022	$-0.52	$-0.36	+30.8%	✓ BEAT
Q1 2022	Feb 22, 2022	$-0.44	$-0.53	-20.5%	✗ MISS
Q4 2021	Nov 1, 2021	$-0.63	$-0.44	+30.2%	✓ BEAT
Q3 2021	Aug 3, 2021	$-0.69	$-0.61	+11.6%	✓ BEAT
Q2 2021	May 4, 2021	$-0.73	$-0.72	+1.4%	✓ BEAT

Frequently Asked Questions about KNSA

What is KNSA's current stock price?

Kiniksa Pharmaceuticals, Ltd. (KNSA) is currently trading at $38.60 per share. The stock has moved -6.13% today.

What is the analyst price target for KNSA?

The average analyst price target for KNSA is $52.50, based on 1 analyst.

What sector is Kiniksa Pharmaceuticals, Ltd. in?

Kiniksa Pharmaceuticals, Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is KNSA's market cap?

Kiniksa Pharmaceuticals, Ltd. has a market capitalization of $2.83 billion, making it a mid-cap company.

Does KNSA pay dividends?

No, Kiniksa Pharmaceuticals, Ltd. does not currently pay a dividend to shareholders.